OMEROS CORP (OMER): Results of Operations and Financial Condition
OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_966798.htm EXHIBIT 99.1 ex_966798.htm Exhibit 99.1 Omeros Corporation Reports Second Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 12, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and develop
How this was made
The 30-second read
Why it matters
Key decision points are (1) YARTEMLEA revenue acceleration and gross-to-net adjustments, (2) capital structure actions via repurchase of 2029 Notes and share buybacks, and (3) a new EMA/CHMP negative opinion that initiates a re-examination process for the European marketing authorization application.
Market read
Traders get a full package of quarterly numbers plus fresh catalysts: US reimbursement support, ongoing buybacks and debt reduction, and a new Europe regulatory negative opinion that can shift expectations for timelines and access.
What to watch
Non-cash gains from mark-to-market on the 2029 Notes can distort earnings quality; traders may focus more on cash burn, adjusted profitability, and the pace of Phase 3/Phase 2 starts than headline net income.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and operational updates for Omeros’ TA-TMA therapy YARTEMLEA (narsoplimab) and pipeline programs.
Ticker impact
Omeros reported Q2 2026 results, including YARTEMLEA gross revenues of $32.2M and a CHMP negative opinion for narsoplimab in TA-TMA.
Likely two-sided reaction risk: upside from accelerating YARTEMLEA revenues and buybacks, offset by uncertainty around the CHMP negative opinion and potential timeline delays in Europe.
The filing is a primary disclosure with multiple decision-relevant items: quarterly financials, cash/operations, 2029 Notes repurchase and share repurchases, plus a fresh CHMP negative opinion that can affect European access and expectations.
Market effects
Reinforces investor attention on TA-TMA and complement/MASP-2 pathway therapeutics, while highlighting regulatory risk in Europe for first-in-class claims.
Europe access uncertainty for narsoplimab in TA-TMA following CHMP negative opinion, despite continued expanded-access availability.
US reimbursement catalysts (J-code effective July 1, NTAP effective Oct 1) may support broader adoption expectations beyond Europe.
Counterpoint
The CHMP negative opinion may be less damaging if re-examination reverses the decision, while US reimbursement changes could keep the revenue trajectory strong.
Key entities
- issuerOmeros Corporation
Nasdaq-listed company reporting Q2 2026 financial results and regulatory/commercial updates for YARTEMLEA.
- productYARTEMLEA (narsoplimab)
Approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA) with reported Q2 2026 gross revenues of $32.2M.
- regulatorEuropean Medicines Agency (EMA) CHMP
Adopted a negative opinion on the marketing authorization application for narsoplimab in TA-TMA, with re-examination requested.
- capital instrument2029 Convertible Notes
Unsecured convertible notes due 2029, partially repurchased in July 2026 to reduce principal and future interest payments.
